首页> 美国卫生研究院文献>Journal of the Endocrine Society >SAT-482 Simultaneous Hashimoto/Graves Disease or Prolonged Hashitoxicosis? A Diagnostic Challenge with Therapeutic Implications
【2h】

SAT-482 Simultaneous Hashimoto/Graves Disease or Prolonged Hashitoxicosis? A Diagnostic Challenge with Therapeutic Implications

机译:SAT-482同时散列/坟墓疾病或延长散毒性病症?治疗意义的诊断挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Some individuals with Hashimoto’s thyroiditis (HT), characterized by anti-TPO antibodies (Abs), can also have positive TSI Abs in up to 20% of cases, without necessarily having Graves disease (GD). Patients with signs of both hyper-and-hypothyroidism with positivity to these two Abs can pose a diagnostic and therapeutic dilemma, as their course is often unpredictable. Clinical Case: A 49-year-old woman was diagnosed with hypothyroidism and took levothyroxine (LT4) for about 1 year, after which she developed symptoms of hyperthyroidism and was switched to methimazole (MMI), which she only took for 1 year. At her initial visit at our clinic she had been off of MMI for 12 months and she was biochemically hyperthyroid (TSH of 0.01 mcIU/ml, f-T4 of 2.26 ng/dl). TSI Abs were positive at 461, but she also tested positive for anti-TPO at 673. Thyroid receptor Abs (TRAb) were also elevated at 54.8. Her vital signs were stable, but she had marked proptosis and complained of eye dryness, so MMI was restarted. A RAIU scan could not be obtained, but a thyroid US showed a heterogeneous and hypervascular gland. On MMI, her thyroid function tests normalized, and her eye disease vastly improved over 2 years. Her MMI dose was progressively decreased until it was stopped completely. On re-evaluation a few months later, she had newly elevated TSH of 8.7 mcIU/ml and low f-T4 of 0.87 ng/dl, with no symptoms of hypothyroidism, so we opted for management with active surveillance instead of starting her on LT4. Her TSI level improved to 240, but remains elevated. Discussion: It is unclear if our patient has a mixed condition with features of both GD and HT, or if she has HT with a very prolonged hyperthyroid phase (hashitoxicosis). Extended periods of hashitoxicosis have been described, the longest reported lasted for 2 years[1]. Simultaneous presentation of GD and HT is very rare, with only a few cases described in the literature. RAIU scan is often diagnostic, showing increased uptake as seen in GD, but patchy areas of decreased uptake can also be seen. In our case it is likely that HT and GD were coexisting, with GD masking the hypothyroidism, until the former remitted with MMI, and her HT took over. Though no RAIU scan was available, the TSI positivity, clinical response of her hyperthyroidism to MMI and the presence of orbitopathy rule in favor of co-existing GD. Decision to treat with LT4 should be weighed against the risk of causing recurrence of hyperthyroidism. Special considerations should be taken in women of childbearing age due to the difficult management that overlapping hyper/hypothyroidism would entail during pregnancy. References: 1. Shahbaz, A et al. Prolonged Duration of Hashitoxicosis in a Patient with Hashimoto’s Thyroiditis: A Case Report and Review of Literature. Cureus. 2018; 10(6):e2804
机译:背景:具有哈希莫氏菌炎(HT)的一些人,其特征在于抗TPO抗体(ABS),也可以具有阳性TSI ABS,高达20%的病例,而不必具有GRAFE疾病(GD)。患有对这两个ABS的阳性阳性的患者患有阳性的症状,可以造成诊断和治疗困境,因为他们的课程通常是不可预测的。临床案例:一名49岁的女性被诊断为甲状腺功能亢进症,并服用约1年的左旋甲苯胺(LT4),之后她开发了甲状腺功能亢进的症状,并切换到甲唑(MMI),她只服用了1年。在她初步访问我们的诊所,她已经脱离了MMI 12个月,她是生物化学上甲状腺功能亢进(TS 0.01 mciu / ml,F-T4为2.26 ng / dl)。 TSI ABS在461处呈阳性,但她还在673中测试抗TPO阳性。甲状腺受体ABS(TRAB)也在54.8升高。她的生命体征稳定,但她有馅目并抱怨眼睛干燥,因此重启。无法获得RAIU扫描,但甲状腺US显示出异构和高血管腺。在MMI上,她的甲状腺功能试验标准化,她的眼病超过2年大幅提高。在完全停止之前,她的MMI剂量逐渐降低。几个月后重新评估,她的TSH患有了8.7麦柳/ mL,低F-T4的0.87 ng / dL,没有甲状腺功能亢进的症状,因此我们选择了主动监测而不是在LT4上启动她。她的TSI水平改善到240,但仍然升高。讨论:目前尚不清楚我们的患者是否具有与GD和HT的特征的混合条件,或者如果她有一个非常长的甲状腺蛋白酶(Hashitoxicosis)。已经描述了延长的斑氏毒性,最长的报告持续了2年[1]。同时呈现GD和HT是非常罕见的,在文献中只描述了一些案例。 Raiu扫描通常是诊断,显示在GD中看到的增加的摄取,但也可以看出降低摄取的斑块区域。在我们的情况下,HT和GD很可能与甲状腺功能减退症一起共存,直到前者汇集了MMI,她的HT接管了。虽然没有RAIU扫描可用,但TSI积极性,甲状腺功能亢进症对MMI的临床响应以及胰腺病变的存在,有利于共同现有的GD。应根据甲状腺功能亢进复发的风险权衡与LT4治疗治疗的决定。由于困难的管理层,在怀孕期间将需要重叠的高甲状腺功能亢进,应特别考虑育龄期的特殊考虑因素。参考文献:1。Shahbaz,A等。患有Hashimoto的甲状腺炎的患者患有患者的长期持续时间:案例报告和文学审查。 Cureus。 2018; 10(6):E2804

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号